Papillary thyroid carcinoma (PTC) · line 1 · Lenvatinib monotherapy (RAI-refractory progressive PTC, 1L systemic)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-LENVATINIB-THYROID-RAI-REF`

ID	`IND-THYROID-PAPILLARY-RAI-REFRACTORY-LENVATINIB`
Type	Indication
Status	pending_clinical_signoff
Diseases	`DIS-THYROID-PAPILLARY`
Sources	`SRC-NCCN-THYROID-2025`

Notes

STUB scaffold. Auto-generated minimal indication so engine can route end-to-end. Pending Clinical Co-Lead review per CHARTER §6.1 dev-mode signoff exemption.

Used By

Algorithms

ALGO-THYROID-PAPILLARY-1L - ALGO-THYROID-PAPILLARY-1L